Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as Buy by Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $115.00 price objective on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 96.58% from the stock’s current price.

A number of other analysts have also recently issued reports on ARWR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They issued a “buy” rating and a $108.00 target price for the company. Piper Sandler reiterated an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Stock Up 0.2%

ARWR traded up $0.13 on Thursday, reaching $58.50. 2,009,461 shares of the company traded hands, compared to its average volume of 2,292,497. The stock’s 50 day moving average price is $76.71 and its 200-day moving average price is $75.99. Arrowhead Pharmaceuticals has a 52-week low of $36.57 and a 52-week high of $95.49. The company has a market cap of $8.24 billion, a price-to-earnings ratio of -26.00 and a beta of 1.29. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.26) earnings per share. On average, sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Versant Capital Management Inc lifted its stake in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. Optiver Holding B.V. lifted its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth $39,000. Finally, Allied Private Wealth LLC acquired a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at $43,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported Phase 1/2a interim data showing deep and durable tau reductions of up to 73% in healthy volunteers. The results represent an early clinical validation that the company’s RNAi technology can deliver siRNA across the blood-brain barrier, a major challenge in developing neurological treatments. Arrowhead ARO-MAPT interim Phase 1/2a clinical data
• Positive Sentiment: The ARO-MAPT announcement prompted favorable coverage, with investors viewing the data as potentially establishing a new platform for treating Alzheimer’s and other tauopathies. Arrowhead reports positive ARO-MAPT data
• Positive Sentiment: UBS initiated coverage with a Buy rating and a $109 price target. Chardan Capital reaffirmed its Buy rating with a $115 target, while HC Wainwright maintained its Buy rating and raised or reiterated a $120 target. These targets imply substantial upside and reinforce the bullish view among analysts.
• Neutral Sentiment: The ARO-MAPT findings are still early-stage and were reported in healthy volunteers; they demonstrate tau knockdown and blood-brain-barrier delivery, but not yet clinical benefits for Alzheimer’s patients. Further trials will need to establish safety, efficacy, and commercial viability. Arrowhead discusses ARO-MAPT interim results and TRiM CNS delivery

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.